Ofloxacin Concentration-toxicity Relationship in the Elderly

Launched by CENTRE HOSPITALIER UNIVERSITAIRE, AMIENS · Jul 29, 2020

Keywords

ClinConnect Summary

This clinical trial is studying how the antibiotic ofloxacin, which is commonly used to treat bone and joint infections, affects elderly patients. Researchers want to understand if there is a link between the amount of ofloxacin in the blood after three days of treatment and any side effects that patients might experience. The goal is to find out if there is a certain level of the drug that could lead to more adverse effects, helping doctors use this medication more safely in older adults.

To participate in this study, you need to be over 65 years old and currently hospitalized for a straightforward bone or joint infection that requires treatment with ofloxacin. Unfortunately, if you have certain health issues, like liver problems, or if you are unable to give consent, you won't be able to join the trial. If you do take part, you’ll be monitored for any side effects while receiving ofloxacin, helping improve our understanding of its safety in older patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients aged over 65 years hospitalized at the University Hospital of Amiens for an uncomplicated bone and joint infections
• • Indication for oral switch to ofloxacin
• Exclusion Criteria:
• • Patient refusing to participate in the study
• • Patient under guardianship or curators or deprived of public rights
• • Any liver or biliary injury
• • Any contraindications to ofloxacin